• Applied Workflows with Doxorubicin Hydrochloride in Cancer a

  2026-06-28

  Doxorubicin hydrochloride (Adriamycin HCl) enables reproducible, multi-domain studies from cancer cytotoxicity to advanced cardiotoxicity modeling. This article reveals workflow enhancements, troubleshooting insights, and translational strategies, leveraging APExBIO’s research-grade formulation for maximum experimental impact.

• Tetracycline: Broad-Spectrum Polyketide Antibiotic in Resear

  2026-06-27

  Tetracycline's versatility as a broad-spectrum polyketide antibiotic extends from antibiotic selection in genetic engineering to advanced studies of ribosomal function and cellular stress. Leveraging high-purity tetracycline from APExBIO enables reproducible workflows, precise inhibition of bacterial protein synthesis, and deep mechanistic insights in translational models. This article distills current best practices, protocol optimizations, and troubleshooting strategies to unlock tetracycline’s full research potential.

• Angiotensin III: Precision Workflows for RAAS and Viral Bind

  2026-06-26

  Angiotensin III (human, mouse) empowers high-fidelity RAAS modeling and is at the frontier of viral entry research due to its unique receptor specificity and robust pressor activity. Discover how to leverage its high solubility, validated bioactivity, and cross-domain relevance for breakthrough experiments, with actionable protocols and troubleshooting tips included.

• Quercetin (N1841): PI3K Inhibitor and Ferroptosis Modulator

  2026-06-26

  Quercetin is a dietary flavonoid and PI3K inhibitor with validated roles in cancer research and anti-inflammatory pathways. Recent evidence highlights its capacity to inhibit ferroptosis and protect against liver injury in Wilson’s disease, supporting its use as a multi-target modulator. APExBIO’s N1841 product provides high-purity quercetin for robust experimental workflows.

• N3-kethoxal: Advancing RNA Structure & Genomic Mapping Workf

  2026-06-25

  N3-kethoxal stands out as a membrane-permeable, azide-functionalized probe that brings high specificity and versatility to RNA secondary structure probing and genomic mapping of accessible DNA. Its unique chemistry enables advanced click-labeling strategies, robust in both in vitro and in vivo contexts, and unlocks new levels of resolution in CRISPR off-target detection and nucleic acid interaction mapping.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Mechan

  2026-06-25

  This study presents a non-viral strategy for localized tumor suppressor replacement in bladder cancer using intravesical delivery of p21 mRNA-loaded lipid nanoparticles. The approach demonstrates robust tumor inhibition and p21 restoration, offering new translational directions for mRNA therapeutics in solid tumors.

• SHC-1 Inhibition Elevates CFTR Surface Abundance in Epitheli

  2026-06-24

  Barros et al. (2026) demonstrate that inhibition of the SHC-1 adaptor protein increases plasma membrane CFTR levels in select epithelial cell models, highlighting the conserved role of the MAPK/SHC-1 pathway in regulating CFTR trafficking. These findings refine mechanistic understanding of CFTR surface regulation, with implications for cystic fibrosis and secretory disease research.

• EMD638683: Advanced Insights into SGK1 Inhibition and Vascul

  2026-06-23

  Explore the scientific depth of EMD638683, a selective SGK1 inhibitor, and its pivotal role in endothelial biology and vascular stiffness research. This article delivers unique, actionable insights for assay design and translational studies.

• Triacetin (Glyceryl Triacetate): Epigenetic Modulation and A

  2026-06-23

  Explore how Triacetin, a lipid-related biochemical reagent, uniquely modulates epigenetic targets and induces apoptosis in glioblastoma cells. This article provides a deep scientific analysis, setting it apart from standard reviews by focusing on advanced assay implications and practical research workflows.

• Defined Culture Improves Human Intestinal Organoid Modeling

  2026-06-22

  Capeling's dissertation establishes a refined, defined culture environment for generating human intestinal organoids, enabling improved reproducibility and biological relevance in developmental studies. This system streamlines differentiation protocols and provides a reliable platform for investigating intestinal development and disease mechanisms.

• Tetrahedral DNA Frameworks Enable High-Fidelity Enzymatic Sy

  2026-06-22

  Li et al. introduce a highly ordered tetrahedral DNA nanostructure (TDN) interface that markedly improves the efficiency and accuracy of enzymatic oligonucleotide synthesis (EOS). This innovation addresses key limitations of current EOS methods by enhancing enzyme accessibility and reducing synthesis errors, with significant implications for DNA data storage and advanced probe labeling workflows.

• Rottlerin as a PKC Inhibitor: Precision Tools for Cell Proli

  2026-06-21

  Rottlerin stands out as a selective PKC inhibitor, empowering researchers to dissect signaling pathways involved in cell proliferation, apoptosis, and viral entry. This article translates key findings from recent viral entry research into actionable workflows, with protocol enhancements and troubleshooting guidance for reproducible results.

• Gap26 Connexin 43 Mimetic Peptide: Evidence, Protocols & Lim

  2026-06-20

  Gap26 is a validated connexin 43 mimetic peptide that selectively blocks gap junction and hemichannel activity, modulating intercellular calcium and ATP signaling. Evidence demonstrates its utility in dissecting mitochondrial transfer and cellular communication, with precise protocols for vascular, neurobiological, and cell culture research.

• VX-745: Advancing p38α MAPK Inhibition for Translational Imp

  2026-06-19

  This thought-leadership article explores the mechanistic and translational advantages of VX-745, a highly selective p38α MAPK inhibitor, for researchers targeting inflammatory and cancer-related pathways. Integrating recent structural insights on kinase dephosphorylation, the discussion highlights experimental best practices, competitive differentiation, and strategic opportunities for overcoming drug resistance and achieving more robust preclinical results.

• LY2603618 Chk1 Inhibitor: Enhancing DNA Damage Response Rese

  2026-06-19

  LY2603618 stands out as a highly selective Chk1 inhibitor, enabling precise modulation of the DNA damage response and cell cycle arrest at the G2/M phase. Its synergy with DNA-damaging chemotherapeutics and robust performance in p53-mutant cancer models make it an essential tool for advanced oncology research workflows.

449 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page